Bimzelx (bimekizumab) prior authorization — coverage criteria for plaque psoriasis, psoriatic arthritis, nr-axSpA, and ankylosing spondylitis
Customize your policy alerts
Sign up for all Alaska Medicaid policy alerts
Know when Alaska Medicaid releases new policies or updates existing guidance.
Monitor payer policy activity
Defines Alaska Medicaid prior authorization criteria, approval/denial rules, quantity limits, and required documentation for bimekizumab (Bimzelx) for indicated adult inflammatory conditions.
No material clinical or coverage changes in this revision.
Coverage / Medical Necessity Criteria
Plaque Psoriasis
Covered when ALL of the following are met
Psoriatic Arthritis
Covered when ALL of the following are met
Non-radiographic Axial Spondyloarthritis
Covered when ALL of the following are met
Ankylosing Spondylitis
Covered when ALL of the following are met
Active inflammatory bowel disease (IBD) is an explicit exclusion to approval for bimekizumab. Requests for therapy will be denied if the patient has active IBD documented in the medical record.
Therapy is not approved when the prior authorization approval criteria are not met. Requests will also be denied if the patient has an active clinically significant infection or is receiving another biologic response‑modifying agent, unless documentation demonstrates these conditions have been resolved or the concomitant therapy has been discontinued per prescribing guidance.
Severity Thresholds and Coding-relevant Criteria
Prior Authorization, Step Therapy, Documentation, and Denial Conditions
Prior authorization required; approval conditioned on meeting indication criteria
Prior authorization is required for bimekizumab; approval is granted only when the patient meets the diagnosis‑specific criteria listed in the coverage criteria sections for each indication.
Step therapy: required prior trials or documented contraindication
Patients must have tried and failed, or have a documented clinical contraindication to, the specified prior therapies outlined for each indication (examples include failure of a preferred TNF antagonist and other agents; for axial disease and ankylosing spondylitis, failure of two different NSAIDs).
- Plaque psoriasis: tried and failed or documented contraindication to a TNF antagonist and at least one other therapy including at least one topical agent (chunk 4).
- Psoriatic arthritis: tried and failed a preferred TNF antagonist and at least one conventional agent (e.g., methotrexate, sulfasalazine) for ≥ 3 months (chunk 5).
- Non-radiographic axial spondyloarthritis and ankylosing spondylitis: tried and failed or documented contraindication to 2 different NSAIDs for ≥ 3 months AND tried and failed or contraindication to a preferred TNF antagonist for ≥ 3 months (chunks 7, 8).
Required baseline documentation and approval durations
Prescriber must submit baseline measures and labs with the PA request; initial approvals are up to 3 months and reauthorizations up to 12 months.
- Plaque psoriasis baseline: PASI score, current patient weight, and liver function enzymes/alkaline phosphatase/bilirubin (chunk 4).
- Psoriatic arthritis baseline: CASPAR score (or equivalent), current patient weight, and liver function enzymes/alkaline phosphatase/bilirubin (chunk 5).
- Approval duration: Initial Approval up to 3 months; Reauthorization Approval up to 12 months (chunk 11).
Denial triggers: missing criteria, infections, concurrent biologics, or active IBD
Requests will be denied if approval criteria are not met, or if the patient has active clinically significant infection, is receiving another biologic response‑modifying agent, or has active inflammatory bowel disease.
- Denial for failure to meet the specific approval criteria in the coverage sections (chunk 9).
- Denial if patient has an active clinically significant infection (chunk 9).
- Denial if patient is receiving another biologic response modifying agent (chunk 9).
- Denial if patient has active inflammatory bowel disease (chunk 9).
Indications, Drug Background, and Definitions
Bimzelx (bimekizumab) is a humanized monoclonal antibody that acts as an antagonist to both interleukin‑17A (IL‑17A) and interleukin‑17F (IL‑17F). It is FDA‑approved for certain adult inflammatory conditions including moderate‑to‑severe plaque psoriasis, psoriatic arthritis, non‑radiographic axial spondyloarthritis with objective signs of inflammation, and active ankylosing spondylitis. The policy references the prescribing information and available clinical trial evidence for safety and efficacy when assessing prior authorization requests.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.